Sight Sciences

Ophthalmic medical device company (NASDAQ: SGHT) developing and commercializing surgical and nonsurgical technologies for prevalent eye diseases. Its Surgical Glaucoma segment markets the OMNI family of implant-free minimally invasive glaucoma surgery systems (OMNI Ergo, OMNI EDGE) and the SION bladeless excisional device; its Dry Eye segment markets the TearCare interventional dry eye system for evaporative dry eye disease. Q2 2026 revenue grew roughly 20% year over year, prompting the company to raise full-year 2026 revenue guidance and lower adjusted operating expense guidance, and the stock gained about 28% in a single August 2026 session.